Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types 1 , 2 , 3 , 4 , 5 . One …

PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma
patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma …

Background Approximately 75% of objective responses to anti–programmed death 1 (PD-1)
therapy in patients with melanoma are durable, lasting for years, but delayed relapses have …

Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed
death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary …

Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated
by T cells, which we characterized in 102 tumor biopsies obtained from 53 patients treated …

Purpose: It has been demonstrated that large numbers of tumor-specific T cells for adoptive
cell transfer (ACT) can be manufactured by retroviral genetic engineering of autologous …

Purpose: Tumor antigen–loaded dendritic cells (DC) are believed to activate antitumor
immunity by stimulating T cells, and CTL-associated antigen 4 (CTLA4)–blocking antibodies …

Background: CTLA4 blocking monoclonal antibodies provide durable clinical benefit in a
subset of patients with advanced melanoma mediated by intratumoral lymphocytic infiltrates. A …

We performed a phase 1/2 trial testing the safety, toxicity, and immune response of a
vaccine consisting of autologous dendritic cells (DCs) transduced with a replication-defective …

Preclinical models predict that blockade of the coinhibitory molecule cytotoxic T lymphocyte–associated
antigen 4 (CTLA4) on lymphocytes results in the release of a cell cycle inhibitory …